Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-48844

Chapman, P B; Hauschild, A; Robert, C; Haanen, J B; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, S J; Sosman, J A; Kirkwood, J M; Eggermont, A M M; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, R J; Flaherty, K T; McArthur, A G (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26):2507-2516.

Published Version
PDF - Registered users only
1092Kb

Abstract

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

Item Type:	Journal Article, refereed, original work
Communities & Collections:	04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
DDC:	610 Medicine & health
Language:	English
Date:	2011
Deposited On:	02 Aug 2011 09:32
Last Modified:	23 Nov 2012 14:45
Publisher:	Massachusetts Medical Society
ISSN:	0028-4793
Publisher DOI:	10.1056/NEJMoa1103782
PubMed ID:	21639808
WoS Citation Count:	705

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page